Where biotech money is moving, what it rewards, and the non-dilutive capital filling the gaps.
SynBioBeta 2027 May 3-6, San Jose, California
Luis
Martinez
Capital Factory
Alex
Hoffmann
Forbion Capital Partners
General Partner
Jenny
Rooke
Genoa Ventures
Managing Director
Omri
Amirav-Drory
NFX
General Partner
Capital Markets, Venture & Philanthropy
Science moves at the pace capital allows. This is where the money is moving.
Science advances at the pace capital allows, and yet funding conditions are tracked with far less rigor than the biology itself.
Venture data in biotech is fragmented, delayed, and siloed by sector, which makes it hard to answer basic questions: where is money actually moving, what are companies raising at, and which stages have quietly gotten harder. This theme takes that seriously, working through investment trends, deal volume, valuations, and stage-by-stage dynamics across programmable biology, not as sentiment but as evidence. It also covers the capital venture cannot supply on its own: philanthropic and non-dilutive funding carrying early-stage, high-risk, and mission-driven work through the years before a return exists.
Every other theme at SynBioBeta describes what is technically possible. This one addresses what gets built, and presses on the question founders and investors are both circling: what does the market reward right now?
Where you’ll meet the people
funding the next decade of biotech.
Funding Trends & Deal Flow
Capital availability and sentiment shape what gets funded and which technologies reach commercialization, yet funding conditions are rarely tracked with the same depth as the science itself — venture data in biotech is often fragmented, delayed, or sector-siloed. This subset covers how capital is actually behaving across the programmable biology industry: VC investment trends, deal volume, valuations, and stage-by-stage funding analysis across the synthetic biology and biotech sector, alongside the role of philanthropic and non-dilutive funding in advancing early-stage and mission-driven research that venture capital alone won’t support.
Meet the Sponsors & Exhibitors
Why People Keep Coming Back
”
SynBioBeta is a who’s who of AI and biology. This is where the future is being built, so don't miss it.
Eric Schmidt
Former CEO
”
Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal.
Surge Biswas
Founder
”
I met Algen at SynBioBeta and later invested in the company. It's exactly the kind of connection that makes the community so valuable.
Bill Tai
Co-founder
”
For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta.
Celestine Schnugg
Founder
Advance Discount Ends Midnight Thursday, December 31. Lock In Your Rate Now.
All passes are fully refundable.
Students: Join our Next-Generation Leaders Program
Secure Your Spot in the Exhibit Hall